Literature DB >> 14992415

Resistance issues and community-acquired respiratory infections.

Daniel F Sahm1.   

Abstract

Antimicrobial resistance, associated with both excessive and inappropriate use of antimicrobial agents, is a global problem. It is a particular problem in the management of community-acquired respiratory infections, which most often result in the use of antimicrobial therapy. Infections caused by resistant and multiresistant pathogens may also result in high hospitalization rates, long lengths of stay, severe illness, and high mortality, all of which have a great impact on health care costs. The Tracking Resistance in the United States Today (TRUST) Program, the largest longitudinal continuous-surveillance program of its kind, has been conducted every year since 1996 and tracks consecutive respiratory seasons on a year-to-year basis to monitor resistance patterns of respiratory pathogens. This article discusses some of the findings of the TRUST Program, particularly trends in Streptococcus pneumoniae resistance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14992415     DOI: 10.1016/s1098-3597(03)90024-x

Source DB:  PubMed          Journal:  Clin Cornerstone        ISSN: 1873-4480


  5 in total

1.  Predominance of 23S rRNA mutants among non-erm, non-mef macrolide-resistant clinical isolates of Streptococcus pneumoniae collected in the United States in 1999-2000.

Authors:  Todd A Davies; Karen Bush; Daniel Sahm; Alan Evangelista
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

2.  Activities of ceftobiprole and other beta-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x.

Authors:  Todd A Davies; Wenchi Shang; Karen Bush
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 3.  Azithromycin extended release: a review of its use in the treatment of acute bacterial sinusitis and community-acquired pneumonia in the US.

Authors:  Tracy Swainston Harrison; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.

Authors:  Nataliya Korzheva; Todd A Davies; Raul Goldschmidt
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

Review 5.  Clinical applications of azithromycin microspheres in respiratory tract infections.

Authors:  Francesco Blasi; Stefano Aliberti; Paolo Tarsia
Journal:  Int J Nanomedicine       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.